We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome.
REDWOOD CITY, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (βSolenoβ) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
PDUFA target action date set for December 27, 2024 FDA currently plans to hold an Advisory Committee meeting REDWOOD CITY, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.44 | -2.71442035815 | 53.05 | 55.56 | 49.69 | 514537 | 52.4743298 | CS |
4 | 5.84 | 12.759449421 | 45.77 | 55.56 | 44.76 | 604059 | 49.55493025 | CS |
12 | 10.81 | 26.4950980392 | 40.8 | 55.56 | 39.41 | 469153 | 47.80541134 | CS |
26 | 10.23 | 24.7220879652 | 41.38 | 55.56 | 36.61 | 453468 | 45.30659938 | CS |
52 | 47 | 1019.52277657 | 4.61 | 55.56 | 4.1127 | 626505 | 35.7928648 | CS |
156 | 50.6972 | 5554.03155127 | 0.9128 | 55.56 | 0.1302 | 674772 | 11.64910705 | CS |
260 | 49.78 | 2720.21857923 | 1.83 | 55.56 | 0.1302 | 773797 | 6.81804323 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions